Liminal BioSciences Inc. (LMNL) and Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) Comparison side by side

This is a contrast between Liminal BioSciences Inc. (NASDAQ:LMNL) and Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) based on their institutional ownership, analyst recommendations, profitability, risk, dividends, earnings and valuation. The two companies are Biotechnology and they also compete with each other.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Liminal BioSciences Inc. 8 0.00 3.27M 0.00 0.00
Alexion Pharmaceuticals Inc. 111 0.67 220.74M 6.04 18.87

Demonstrates Liminal BioSciences Inc. and Alexion Pharmaceuticals Inc. earnings per share, gross revenue and valuation.

Profitability

Table 2 provides us Liminal BioSciences Inc. and Alexion Pharmaceuticals Inc.’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Liminal BioSciences Inc. 41,869,398.21% 0% 0%
Alexion Pharmaceuticals Inc. 199,566,042.85% 14.9% 10.3%

Analyst Recommendations

The next table highlights the given recommendations and ratings for Liminal BioSciences Inc. and Alexion Pharmaceuticals Inc.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Liminal BioSciences Inc. 0 0 0 0.00
Alexion Pharmaceuticals Inc. 0 1 10 2.91

Meanwhile, Alexion Pharmaceuticals Inc.’s consensus target price is $152.07, while its potential upside is 35.14%.

Insider and Institutional Ownership

Institutional investors owned 0% of Liminal BioSciences Inc. shares and 96.1% of Alexion Pharmaceuticals Inc. shares. Comparatively, Alexion Pharmaceuticals Inc. has 0.1% of it’s share owned by insiders.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Liminal BioSciences Inc. -2.09% -25.03% -67% -97.61% -98.65% -97.12%
Alexion Pharmaceuticals Inc. -0.04% 6.81% 7.04% -2.17% -5.91% 16.98%

For the past year Liminal BioSciences Inc. had bearish trend while Alexion Pharmaceuticals Inc. had bullish trend.

Summary

Alexion Pharmaceuticals Inc. beats on 12 of the 12 factors Liminal BioSciences Inc.

Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes life-transforming therapeutic products. The company offers Soliris (eculizumab), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and atypical hemolytic uremic syndrome (aHUS), a genetic disease. It also provides Strensiq (asfotase alfa), a targeted enzyme replacement therapy for patients with hypophosphatasia (HPP); and Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency. In addition, the company conducts Phase III clinical trials for Soliris (eculizumab) for the treatment of myasthenia gravis and neuromyelitis optica spectrum disorder; and Phase II clinical trials for antibody mediated rejection in presensitized renal transplant patients. Further, it develops cPMP (ALXN 1101) that is in Phase II/III trial for treating metabolic disorders; SBC-103, which is in Phase I/II clinical trials for the treatment of metabolic disorders; ALXN 1210 (IV) that is in Phase III clinical trials for the treatment of PNH and aHUS; and ALXN 1210, which is in Phase I clinical trials to evaluate subcutaneous delivery. The company serves distributors, pharmacies, hospitals, hospital buying groups, and other health care providers, as well as governments and government agencies in the United States, Europe, the Asia Pacific, and internationally. Alexion Pharmaceuticals, Inc. has agreements with X-Chem Pharmaceuticals (X-Chem) to identify novel drug candidates from X-Chem's proprietary drug discovery engine; and Moderna Therapeutics, Inc. (Moderna) that provides the option to purchase drug products for the development and commercialization of Moderna's messenger RNA therapeutics to treat rare diseases. The company was founded in 1992 and is headquartered in New Haven, Connecticut.